Tor McCaul – Managing Director – Comet Ridge Limited (ASX: COI) is a publicly listed Australian energy company focused on the development of natural ga
Copyright 2023 – Finance News Network
01 Apr 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari introduces the company, discussing the use of radiopharmaceuticals for cancer treatment and the company's upcoming trial in non-small cell lung cancer.
29 Jul 2022 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent key announcements, including the appointment of a US sales team, the securing of a US patent, quarterly results, and the year ahead.
24 Apr 2020 - Telix Pharmaceuticals (ASX:TLX), Chief Business Officer, David Cade talks about its prostate cancer imaging product, diagnostic and therapeutic products, partners and key priorities for 2020.
16 Sep 2022 - eCargo Holdings Limited (ASX:ECG) Group CEO Laurence Lun discusses highlights from the company's interim results, operations during lockdown and future milestones.
30 Jul 2024 - Roger Cressey - Executive Director, Commercial & Operations - Gold Hydrogen (ASX:GHY) specialises in natural power from hydrogen, a sustainable form of natural gas harvested in Australia.
29 Nov 2023 - Equinox Resources Limited (ASX:EQN) CEO Zac Komur discusses the company's move to apply for a large rare earths tenement in Brazil, and the attractions of the jurisdiction.
12 Oct 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company's new Phase 2 trial in soft tissue sarcoma and the outlook ahead.
27 Feb 2020 - NetLinkz Limited (ASX:NET) Executive Chairman and CEO, James Tsiolis talks about the significance of the company's agreement to provides its Virtual Secure Network to a World Bank-sponsored initiative to improve water sanitation services in selected areas of the Deyang Municipality of Sichuan Province.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.